Published on
Oncology- Electron Beam Therapy
I. Electron Beam Therapy vs. Photon Radiotherapy
A. Fundamental Difference: Electron beams, unlike photons, possess charge. This leads to frequent interactions within tissue, resulting in a defined range of penetration and negligible dose beyond that range. Photons penetrate deeper.
B. Electron Beam Advantages:
  • Limited penetration: Ideal for superficial tumors, minimizing damage to underlying structures.
  • Negligible exit dose: Reduces radiation exposure to tissues beyond the target.
  • Superficial tumor treatment: Particularly useful for skin cancer, head and neck cancers, and breast cancer.
  • Reduced normal tissue dose: Minimizes damage to critical structures like the spinal cord and lungs.
C. Photon Beam Advantages:
  • Deep penetration: Suitable for deep-seated cancers.
  • Skin sparing: Delivers less radiation to the skin surface.
  • Easier beam matching: Facilitates precise treatment planning with crossfire techniques.
II. Production of Electron Beams
  • Linear Accelerators: Most radiotherapy facilities use linear accelerators to produce both X-ray and electron beams.
  • Beam Collimation: Due to significant air scattering, collimators (cones or trimmer bars) are used to shape the beam near the skin's surface. Further shaping can be achieved with lead apertures or lead sheets placed directly on the skin.
III. Dosimetric Characteristics of Electron Beams
A. Depth Dose Characteristics:
  • Dose buildup: The dose increases gradually to a maximum and then drops sharply to near zero at the practical range.
  • Practical Range (Rp): The depth at which the dose becomes negligible. Approximated by Rp ≈ E0 / 2. (E0 = incident beam energy in MeV)
  • Clinically Useful Range (d80): The depth where the dose falls to 80% of its maximum. Approximated by d80 ≈ E0 / 3.
  • Surface Dose: Significantly higher for electron beams than photon beams (85-95% of maximum dose, depending on energy).
B. Effect of Incident Energy: Higher incident energy (E0) leads to greater penetration depth. Common energies range from 6-15 MeV.
C. Beam Profile and Penumbra:
  • Larger Penumbra: Electron beams have a larger penumbra (area of dose falloff) than photon beams. A 10x10 cm² beam might only deliver a clinically useful dose to an 8x8 cm² area.
  • Abutment Challenges: The large penumbra makes combining electron and photon beams difficult, hindering uniform dose delivery across field junctions.
IV. Key Concepts to Remember
  • Charge and Interaction: Electrons' charge leads to their limited penetration and well-defined range.
  • Superficial vs. Deep: Electron beams are for superficial tumors, photons for deep-seated ones.
  • Penumbra: Electron beams have a larger penumbra than photon beams, affecting treatment planning.
  • Range Calculation: Understand the approximations for practical and clinically useful range based on incident energy.
  • Surface Dose: Electron beams have a higher surface dose than photon beams.



Picture
Published on
Oncology-Recent Advances in External Beam Radiotherapy (EBRT)
I. Improved Accuracy and Precision
A. Volume Definition:
  • Past: Planning scans relied on diagnostic scanners, resulting in less precise tumor volume definition.
  • Present: High-resolution CT simulators are standard. 3D tumor volume definition is now accurate even for palliative treatments. Fusion of CT with MRI and PET scans further refines this for radical treatments.
B. Image-Guided Radiotherapy (IGRT):
  • Past: A 1cm margin was added to the Clinical Target Volume (CTV) to account for positioning errors. Megavoltage X-rays provided low-quality confirmation images.
  • Present:
    • Electronic Portal Imaging Devices (EPIDs): Replaced port films, offering improved image quality. Online imaging corrects misalignments before treatment, while offline review identifies recurring setup errors.
    • Intra-treatment Imaging: Precise tumor location is confirmed during treatment using:
      • Fiducial markers (e.g., gold seeds)
      • Ultrasound
      • Cone beam CT (mounted on the linear accelerator) for 3D online imaging.
II. Minimizing Radiation Exposure to Organs at Risk & Higher Tumor Doses
A. Inverse Planned Intensity-Modulated Radiotherapy (IMRT):
  • Mechanism: Computer optimization varies radiation beam intensity to meet dose constraints for healthy organs while delivering prescribed doses to the tumor (CTV and Gross Tumor Volume - GTV). This is achieved through:
    • Step and shoot: Superimposing static uniform intensity segments.
    • Dynamic MLC delivery: A shaped sliding window across the field.
    • Tomotherapy: Multiple arcs with intensity modulated by dynamic MLCs.
  • Benefits: Reduced late effects on normal tissues with equivalent cancer control compared to conventional radiotherapy, particularly in prostate and head/neck cancers. Promising results in lung and gynecological cancers suggest it may replace 3D conformal radiotherapy (CRT) for many radical treatments.
  • Drawback: Significantly increases the workload of the physics team due to the extensive time (at least 2 hours per patient) required for meticulous volume definition.
B. Four-Dimensional (4D) Therapy Planning and Delivery:
  • Addresses the challenge of: Treating mobile structures (e.g., lung cancers moving with respiration).
  • Method: Links 4D CT planning (tumor volume defined at each respiratory phase) to treatment delivery during the expiratory phase for optimal coverage with minimal field size.
C. Stereotactic Radiotherapy:
  • Established for: Intracranial conditions (benign tumors, arteriovenous malformations).
  • Method: High precision (1-2mm) treatment of small lesions (<1cm3) using an external 3d coordinate system and stereotactic fixation. typically uses 1-3 large fractions (12-20 gy).< />pan>
  • Recent expansion: Successful treatment of small malignancies in the brain, lung, and liver. IGRT facilitates accuracy in sites unsuitable for localization frames.
III. Key Terms & Concepts to Remember:
  • CTV: Clinical Target Volume
  • GTV: Gross Tumor Volume
  • EPID: Electronic Portal Imaging Device
  • IMRT: Intensity-Modulated Radiotherapy
  • MLC: Multileaf Collimator
  • IGRT: Image-Guided Radiotherapy
  • 4D: Four-Dimensional (referring to respiratory gating)
Picture
Published on
Oncology-External Beam Radiotherapy: Progress & Techniques
This study guide summarizes advancements in external beam radiotherapy, focusing on 3D planning and conformal treatment.
I. Three-Dimensional (3D) Radiotherapy Planning:
  • Revolutionizing Factor: The most significant advancement in the last 20 years is the integration of cross-sectional imaging (primarily CT scans) into radiotherapy planning. This shift enables:
    • Accurate Target Definition: Precise delineation of tumors and critical structures.
    • Precise Dose Calculation: More accurate determination of radiation dosage.
    • True 3D Planning: Allows for:
      • Reduced Normal Tissue Damage: Minimizing harm to healthy tissue.
      • Increased Tumor Dose: Delivering higher radiation doses to the cancerous target.
      • Improved Therapeutic Index: Optimizing the balance between tumor control and side effects.
Key takeaway: 3D planning using CT scans significantly improves accuracy and allows for better treatment optimization, leading to improved outcomes.
II. Conformal Treatment and Multileaf Collimators (MLCs):
  • Goal: The primary goal of radiotherapy has always been to precisely conform the high-dose radiation to the target tumor while sparing surrounding healthy tissue.
  • Traditional Limitations: Until the 1990s, rectangular beams with limited blocking techniques resulted in unnecessary irradiation of normal tissue.
  • Advancements:
    • Shaped Alloy Blocks: Improved conformation by manually placing shaped blocks to partially obstruct the radiation beam.
    • Multileaf Collimators (MLCs): A significant advancement integrated into modern linear accelerators. MLCs allow for computer-controlled shaping of the radiation beam using numerous 0.5cm-wide leaves. This enables highly precise shaping of the radiation field.
  • Clinical Significance: By minimizing high-dose radiation to normal tissue, MLCs enable higher radiation doses to the tumor, potentially improving tumor control without increasing the risk of side effects (morbidity).
Key takeaway: MLCs are a crucial technology for conformal radiotherapy. They allow for precise shaping of the radiation beam, maximizing tumor dose while minimizing damage to healthy tissues. This improves the therapeutic ratio, aiming for better tumor control with fewer side effects.


Picture
Published on
Oncology- Radiotherapy Fractionation

I. Core Concepts:
  • Objective of Fractionation: To determine the optimal combination of total radiation dose (Gy), number of doses (fractions), and overall treatment time to effectively target cancer while minimizing damage to healthy tissues.
  • Linear Quadratic (LQ) Model: This model describes how tissues respond to radiation. Early-reacting tissues (e.g., skin) show a linear relationship between dose and damage (α component). Late-reacting tissues (e.g., spinal cord) exhibit a quadratic relationship, meaning damage increases disproportionately with dose (β component). The LQ model supports the use of many small fractions to minimize late-reacting tissue damage.
II. Fractionation Schedules:
Two main approaches exist:
A. Few Large Daily Fractions:
  • Advantages: Fewer patient visits, less resource consumption, faster tumor response, reduced tumor repopulation during treatment.
  • Disadvantages: Limits total safe dose, increases risk of late tissue damage, reduced reoxygenation potential (which improves radiotherapy effectiveness), often insufficient to eradicate all cancer cells.
B. Many Small Daily Fractions:
  • Advantages: Less severe acute reactions (due to longer treatment time), reduced late tissue damage, allows for higher total dose, maximizes reoxygenation, potentially eradicates all cancer cells, allows dose reduction if acute reactions are unexpectedly severe.
  • Disadvantages: Increased resource and patient demand, potential for tumor repopulation during prolonged treatment, prolonged acute reactions may require supportive care.
III. Tumor and Tissue Radiosensitivity:
  • Tumor Radiosensitivity: Varies widely. Some tumors (lymphoma, seminoma) are highly radiosensitive, requiring lower doses. Others (gliomas, sarcomas) are radioresistant.
  • Normal Tissue Tolerance Doses (2Gy per fraction): These are maximum doses before significant late damage occurs:
    • Testis: 2 Gy
    • Lens of the eye: 10 Gy
    • Whole kidney: 20 Gy
    • Whole lung: 20 Gy
    • Spinal cord: 50 Gy
    • Brain: 60 Gy
  • Inter-fraction Interval: At least 6 hours should separate fractions to allow for tissue repair. With once-daily fractionation, nearly all repair occurs before the next treatment.
IV. Advanced Fractionation Techniques:
  • Hyperfractionation: Delivers many small fractions (<2gy) to increase total dose without increasing late tissue damage. may involve weekend treatments or multiple daily treatments.< />pan>
  • Accelerated Radiotherapy: Shortens overall treatment time to reduce tumor repopulation during treatment. Often combined with hyperfractionation (e.g., ChaRT regimen). Example: ChaRT (Continuous Hyperfractionated Accelerated RadioTherapy) delivers 54 Gy in 1.5 Gy fractions three times daily for 12 days.
V. Treatment Intent and Regimen Selection:
A. Radical Radiotherapy (Curative Intent):
  • Goal: Highest tolerable dose for maximal cancer eradication.
  • Lower doses used for highly radiosensitive tumors or microscopic residual disease.
  • Multiple daily fractions (~2Gy) minimize late damage.
  • Significant acute toxicity is acceptable due to potential survival benefit.
  • Requires patient fitness for daily attendance.
B. Palliative Radiotherapy (Symptom Relief):
  • Goal: Quick symptom relief, may not impact survival significantly.
  • Lowest effective dose and fraction number are preferred.
  • Avoid prolonged acute damage; late effects may be irrelevant.
  • High-dose palliative radiotherapy may be appropriate in specific advanced cases with durable local disease control as a goal and reasonable life expectancy.
VI. Key Considerations for Studying:
  • Understand the LQ model: This is fundamental to understanding why fractionation is used.
  • Compare and contrast: Clearly differentiate between few large vs. many small fractions, highlighting advantages and disadvantages of each.
  • Know tolerance doses: These are crucial for safe treatment planning.
  • Understand advanced techniques: Grasp the principles behind hyperfractionation and accelerated radiotherapy.
  • Distinguish treatment intent: Recognize how treatment goals (radical vs. palliative) influence regimen selection.




Picture
Published on
Pathology-External Beam Radiotherapy (EBRT)
I. Types of EBRT
A. Superficial X-ray Therapy (80-300 kV): Used for superficial tumors (skin, ribs). Low-energy X-rays are generated by accelerating electrons in an X-ray tube, which then strike a tungsten anode causing bremsstrahlung radiation. Beam size is controlled by metal applicators.
B. Cobalt Teletherapy (Co-60): Uses gamma rays (1.25 MeV average energy) from Co-60 source for deeper tumors. Requires high source strength (around 350 TBq) for adequate dose rate.
C. Megavoltage Radiotherapy (4-20 MV): Most common method, using linear accelerators to produce high-energy X-rays. Offers advantages over Co-60: * Higher penetration * Higher dose rate * Better collimation (precise beam targeting)
D. Electron Therapy (4-20 MeV): Linear accelerators can also generate electron beams. These are suitable for superficial tumors, providing uniform treatment to a specific depth with a rapid dose fall-off beyond that depth. Depth of penetration depends on electron energy (e.g., 6 MeV ≈ 1.5 cm, 20 MeV ≈ 5.5 cm). Offers an alternative to kilovoltage X-rays for superficial tumors.
Limitations of Low-Energy X-ray Beams:
  • Unsuitable for deep-seated malignancies (thorax, abdomen, pelvis).
  • High skin dose.
  • Rapid dose fall-off with depth.
  • Higher bone dose compared to soft tissue.
II. Features of Megavoltage X-rays
  • High dose delivered at depth.
  • Maximum dose below the skin surface (skin-sparing effect).
  • Exponential dose fall-off with depth.
  • Sharp dose fall-off at beam edge (penumbra).
  • Beam shape modification via metal blocks or multileaf collimators.
  • Dose gradient creation using metal filters or wedges.
  • Treatment from any direction is possible.
  • Crossfire technique (2-4 beams) enhances target dose while sparing normal tissues.
III. EBRT Planning Process (Six Steps)
Step 1: Beam Dosimetry: Measuring the dose distribution pattern of each linear accelerator using an ionization chamber in a water tank. Calibration factors (output factors) are determined to calculate irradiation time for a specified dose.
Step 2: Planning Computer: Computer software uses measured beam data and algorithms to account for tissue density variations (often from CT scans) in dose calculations. Simpler planning can be done using tables or plots.
Step 3: Target Drawing: Defining the target volume to be irradiated. This includes: * GTV (Gross Tumor Volume): Visible tumor on imaging or clinical examination. * CTV (Clinical Target Volume): GTV plus surrounding tissue with potential microscopic tumor cells. * PTV (Planning Target Volume): CTV plus margins to account for setup uncertainties (patient positioning, organ movement, machine calibration). Critical organs (spinal cord, eyes, kidneys) are also defined.
Step 4: Dose Planning: Designing a treatment plan to uniformly irradiate the target while keeping critical organ doses within tolerance. Adjustable parameters include: * Patient position * Beam size & shape * Beam direction * Number of beams * Relative dose per beam (beam weight) * Wedging * Compensators
Step 5: Treatment Verification: Ensuring correct beam positioning and avoiding critical organ over-irradiation. Methods include: * Radiographs on a simulator. * Megavoltage radiographs or EPIDs (Electronic Portal Imaging Devices) during treatment. * In vivo dosimetry (thermoluminescence dosimeters) – the gold standard for radical treatments.
Step 6: Treatment Prescription and Delivery: The oncologist prescribes the dose, fractionation schedule, and beam configuration. This information is entered into the linear accelerator's computer system to control treatment delivery.


Picture
Published on
Oncology- Prophylactic Cancer Surgery
I. Conditions Warranting Prophylactic Surgery:
The following conditions significantly increase cancer risk and may necessitate preventative surgery:
A. Cryptorchidism (Undescended Testis): * Procedure: Orchidopexy (surgical repositioning of the testis) or, less frequently, orchidectomy (testicular removal). * Rationale: Undescended testes are at higher risk of developing testicular cancer.
B. Familial Adenomatous Polyposis (FAP): * Procedure: Total colectomy with ileal pouch-anal anastomosis (creation of an internal pouch to replace the colon). * Rationale: FAP leads to numerous colon polyps, many of which are precancerous. Total colectomy drastically reduces colon cancer risk.
C. Ulcerative Colitis: * Procedure: Total colectomy. * Rationale: In cases of extensive ulcerative colitis (>10 years) with evidence of dysplasia (precancerous cell changes) on biopsy, total colectomy may be necessary to prevent colorectal cancer.
D. Multiple Endocrine Neoplasia (MEN) Type 2: * Procedure: Total thyroidectomy. * Rationale: MEN type 2 significantly increases the risk of medullary thyroid carcinoma. Early thyroidectomy is a preventative measure.
E. BRCA1/2 Gene Mutations: * Procedure: Prophylactic bilateral mastectomy (with optional reconstruction) and/or laparoscopic oophorectomy (ovary removal). * Rationale: BRCA1/2 mutations substantially increase the risk of breast and ovarian cancers. While prophylactic surgery is an option, the recent NICE (2013) approval of tamoxifen as a prophylactic drug for BRCA1/2 carriers might reduce the demand for surgery – this remains to be evaluated.
II. Crucial Considerations:
  • Patient Counseling: Extensive counseling is essential before recommending prophylactic surgery due to the significant physical and psychological impact. Risks and benefits must be carefully weighed.
  • Alternative Treatments: Note that in some cases, like BRCA1/2 mutations, pharmacological interventions (e.g., tamoxifen) may offer alternatives to surgery.
  • High-Risk Individuals Only: Prophylactic cancer surgery is reserved for individuals with a significantly increased risk of developing specific cancers, not for the general population.
Picture
Published on
Picture

Oncology-Radiobiology of Normal Tissues

I. Mechanisms of Radiation Damage:

  • Apoptosis: Programmed cell death occurring within 24 hours of irradiation. Primarily affects specific cell types (e.g., some hematopoietic cells, salivary gland cells). Often clinically insignificant due to tissue redundancy and stem cell replacement.
  • Loss of Reproductive Capacity: Reduces the ability of cells to proliferate. The timing of damage manifestation depends on the tissue's cell renewal rate, leading to the distinction between acute and late effects. This is the predominant mechanism in most tissues.

II. Radiosensitivity:

Radiosensitivity varies greatly between tissues (see Table 1).

Radiosensitivity

Tissue

Highly Sensitive

Lymphocytes, Germ cells

Moderately Sensitive

Epithelial cells

Resistant

CNS, Connective tissue

Table 1: Radiosensitivity of Normal Tissues

III. Acute vs. Late Effects:

  • Acute Effects (within 8 weeks of treatment): Primarily affect rapidly proliferating tissues (skin, mucosa, hematopoietic system). Predominantly caused by loss of reproductive capacity, impacting cell replacement. Severity depends on total dose and treatment duration. Complete recovery is usually expected with properly selected treatment doses. Examples include erythema, desquamation, mucositis. The speed of recovery depends on stem cell survival.
  • Late Effects (months to years after treatment): Primarily affect slowly proliferating tissues (lung, kidney, heart, CNS, connective tissue). Severity depends on total dose and dose per fraction (smaller fractions offer protection). Recovery may be incomplete. Examples include fibrosis, telangiectasia, radiation pneumonitis, nephropathy, cardiomyopathy. Late effects are not always predictable from the severity of acute reactions.

IV. Specific Tissue Responses:

  • Skin: Acute – erythema, desquamation, ulceration (if severe). Late – atrophy, fibrosis, telangiectasia.
  • Oral Mucosa: Acute – erythema, ulceration. Late – dry mouth.
  • Gastrointestinal Tract: Acute – mucositis (oesophagitis, nausea/vomiting, diarrhoea, tenesmus). Late – ulceration, fibrosis, obstruction, necrosis.
  • Central Nervous System (CNS): No acute reaction. Late – demyelination (somnolence, Lhermitte's syndrome), radiation necrosis.
  • Lung: Acute – airway obstruction (with large single doses). Late – pneumonitis, fibrosis.
  • Kidney: No acute response. Late – nephropathy (proteinuria, hypertension, renal failure).
  • Heart: Late – pericarditis, cardiomyopathy, conduction blocks.

V. Normal Tissue Tolerance to Retreatment:

Some tissues (e.g., CNS) show significant recovery from subclinical radiation injury, allowing safe retreatment in certain circumstances.

VI. Carcinogenesis:

Radiation-induced DNA damage can lead to secondary malignancies (leukemias, solid tumors) years after exposure. The thyroid and breast are particularly susceptible, especially in childhood/young adulthood. This risk must be weighed against the risk of cancer recurrence.

VII. DNA Repair:

The body can repair some radiation-induced DNA damage. A minimum 6-8 hour gap between radiotherapy fractions is necessary for sufficient repair to prevent excessive normal tissue damage. Hereditary DNA repair defects can significantly increase the risk of severe normal tissue reactions to radiotherapy.

VIII. Hypoxia:

Hypoxic (oxygen-deficient) cells are less sensitive to radiation. Tumor hypoxia is common and can be aggravated by anemia. Tumor response and subsequent reoxygenation during fractionated radiotherapy can enhance tumor cell kill.

Published on

Oncology -Radiation Oncology

I. Introduction to Radiation Oncology (Radiotherapy)

  • Definition: Treatment of malignant disease using ionizing radiation, primarily high-energy X-ray beams (External Beam Radiotherapy - EBRT).
  • Significance: Arguably the most important non-surgical cancer therapy, used in over 50% of cancer patients.

II. Historical Perspective: Key Milestones

This timeline highlights the evolution of radiotherapy techniques and understanding:

Year

Milestone

Significance

1896

Discovery of X-rays

Foundation of radiotherapy.

1898

Discovery of radium

Provided another source of ionizing radiation for treatment.

1899

Successful skin cancer treatment with X-rays

First documented successful cancer treatment using radiation.

1915

Cervical cancer treatment with radium implant

Introduction of brachytherapy (internal radiation therapy).

1922

Cure of laryngeal cancer with X-ray therapy

Demonstrated curative potential of external beam radiotherapy (EBRT).

1928

Roentgen defined as radiation exposure unit

Standardized radiation measurement.

1934

Dose fractionation principles proposed

Crucial development for optimizing treatment and minimizing side effects.

1950s

Radioactive cobalt teletherapy (1MV energy)

Advancement in technology for delivering radiation.

1960s

Megavoltage X-rays from linear accelerators

Significant improvement in radiation delivery precision and depth.

1990s

3D radiotherapy planning

Enhanced precision in targeting tumors.

2000s

IMRT, IGRT, Stereotactic radiotherapy

Advanced techniques for highly precise and targeted radiation delivery.

III. Mechanism of Action

  • Energy Absorption: X-rays passing through tissue cause ionization of molecules, producing fast-moving electrons and free radicals.
  • DNA Damage: The most crucial biological effect is DNA damage, including double-strand breaks. This damage leads to cell death, particularly in rapidly dividing cancer cells.
  • Unit of Dose: Gray (Gy) - energy absorbed per unit mass (J/kg).

IV. Fractionated Radiotherapy

  • Principle: Delivering radiation in small, daily doses (fractions) over several days or weeks.
  • Benefits:
    • Preferential sparing of normal tissue: Allows higher total doses to be safely administered.
    • Increased cancer cell kill: While minimizing damage to healthy tissue.
  • Mechanism: Allows normal tissue repair between fractions, while cancer cells, which often have impaired repair mechanisms, accumulate damage leading to their death.
Picture
Published on

Pathology- Dementia with Lewy Bodies (DLB)

I. Definition & Epidemiology

  • Definition: DLB is a neurodegenerative disease. Clinically, it presents as dementia. Histopathologically (microscopically), it's characterized by the presence of Lewy bodies in brain neurons (both cortical and subcortical).
  • Epidemiology:
    • Second most common cause of dementia.
    • Prevalence: ~5% in individuals >85 years old.
    • Slightly more prevalent in men.

II. Etiology & Pathogenesis

  • Etiology (Cause): Unknown.
  • Pathogenesis (Mechanism): The accumulation of Lewy bodies within neurons is believed to cause neuronal damage and subsequent cell loss, leading to the clinical manifestations of DLB.

III. Clinical Presentation & Differentiation from Alzheimer's Disease (AD)

  • Presentation: Progressively worsening dementia, similar to Alzheimer's Disease (AD).
  • Key Distinguishing Features from AD: This is crucial for diagnosis! DLB presents with:
    • Fluctuating cognition: Mental clarity varies significantly throughout the day or week.
    • Recurrent visual hallucinations: Patients experience vivid, often repetitive, visual hallucinations.
    • Parkinsonism: Features of Parkinson's disease, such as tremors, rigidity, and slow movement, may be present.

IV. Macroscopic & Microscopic Findings (Pathology)

  • Macroscopy (Gross Examination):
    • Cerebral atrophy (brain shrinkage), particularly in the temporal and parietal lobes.
    • Loss of pigment in the substantia nigra (a brain region crucial for movement control).
  • Histopathology (Microscopic Examination):
    • Lewy bodies: Intracytoplasmic (within the cell's cytoplasm) inclusions composed of α-synuclein, ubiquitin, and parkin. These are the hallmark of DLB.
    • AD-like changes: Amyloid plaques and neurofibrillary tangles (characteristic of Alzheimer's) are often present but areas typically severely affected in AD (like the hippocampus) are usually spared in DLB. This is a critical differentiator.

V. Prognosis

  • Highly variable, but the average survival after diagnosis is 5-7 years.

VI. Summary Table for Comparison with Alzheimer's Disease

Feature

Dementia with Lewy Bodies (DLB)

Alzheimer's Disease (AD)

Hallmark Feature

Lewy bodies (α-synuclein, ubiquitin, parkin)

Amyloid plaques and neurofibrillary tangles (tau protein)

Cognition

Fluctuating

Progressive decline, typically more gradual

Visual Hallucinations

Frequent, recurrent

Less common

Parkinsonism

Often present

Usually absent

Hippocampus

Usually spared

Severely affected
Published on
Pathology-Alzheimer's Disease
I. Definition & Epidemiology:
  • Definition: Alzheimer's disease (AD) is a neurodegenerative disorder clinically characterized by dementia and histopathologically by neuronal loss in the cerebral cortex, accompanied by amyloid plaques and neurofibrillary tangles. Crucially, it's the most common cause of dementia.
  • Epidemiology:
    • Incidence dramatically increases with age (5% >65 years old, 20% >80 years old).
    • Represents a significant socioeconomic burden on healthcare systems.
II. Aetiology & Pathogenesis:
  • Aetiology (Cause): The cause is unknown in most cases. A small percentage are familial, linked to genetic mutations in the amyloid precursor protein (APP) gene on chromosome 21.
  • Pathogenesis (Mechanism):
    • AD is considered a "proteinopathy," focusing on the abnormal accumulation of amyloid-beta (Aβ) and tau proteins.
    • Aβ peptides are derived from APP through secretase enzymes.
    • The exact mechanism by which Aβ and tau accumulation leads to neuronal loss remains unclear—this is a key area of ongoing research.
III. Clinical Presentation:
  • Early Stages: Begins with memory loss, especially recent memory and new learning difficulties. Progressive decline in daily activities (finances, shopping).
  • Middle Stages: Loss of motor skills impacts dressing, cooking, and cleaning.
  • Late Stages: Agitation, restlessness, wandering, and disinhibition emerge, causing distress for family and caregivers. Eventually, speech loss, immobility, and incontinence occur.
IV. Macroscopic & Microscopic Findings:
  • Macroscopy (Gross Anatomy):
    • Reduced brain weight (often <1000g).< />pan>
    • Cortical atrophy, particularly in the temporal lobe and hippocampus.
  • Histopathology (Microscopic Anatomy):
    • Key Features: Abundant neuritic plaques and neurofibrillary tangles in the cerebral cortex, alongside neuronal and synaptic loss.
    • Neuritic Plaques: Spherical collections of distorted neuronal processes around a central amyloid core, primarily composed of Aβ protein.
    • Neurofibrillary Tangles: Intracellular accumulations of paired helical filaments within neurons; mainly composed of tau protein.
V. Prognosis:
  • Death typically occurs approximately 10 years post-diagnosis, often due to complications like pneumonia.
Key Concepts to Master:
  • Amyloid-beta (Aβ) plaques: Extracellular deposits, key hallmark of AD.
  • Neurofibrillary tangles: Intracellular accumulations of tau protein, another hallmark of AD.
  • APP (Amyloid Precursor Protein): A protein implicated in familial forms of AD.
  • Tau protein: A microtubule-associated protein whose abnormal accumulation contributes to neurofibrillary tangles.
  • Proteinopathy: A disease caused by misfolded or aggregated proteins.
  • The relationship between Aβ and tau accumulation and neuronal death needs further study.
Picture

Kembara Xtra 

Facts about medicine and its subtopic such as anatomy, physiology, biochemistry, pharmacology, medicine, pediatrics, psychiatry, obstetrics and gynecology and surgery.